Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Sponsor
Abbott
Study ID
NCT00646191
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adalimumab — DRUG
    40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
  • adalimumab — DRUG
    40 mg weekly through Week 48 (OL Week 12 - 48)
  • adalimumab — DRUG
    80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse

Study Details

Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Key Dates

Start date
Mar 31, 2003
Status verified
Mar 2008
Primary completion
Jun 30, 2004

Study Design

Enrollment
137 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: A
  • Active Comparator: B
  • Active Comparator: C

Primary Outcome Measure

Psoriasis Area and Severity Index [ Time Frame: Week 12 ]

Related Studies